Milestone
Portfolio company EpilepsyGTx raised $33M Series A to advance EPY201 gene therapy through Phase 1/2a clinical trials for focal refractory epilepsy.
EpilepsyGTX
DEC 10, 2025
Every public signal F4 has attached to this firm, with sources and cross-entity links.
EpilepsyGTX